Real Estate
Home›Real Estate›Industry›CBRE warns life sciences deal risk from unintegrated b…
CBRE warns life sciences deal risk from unintegrated biotech CRE
CBRE estimates preventable real estate-related risks could total about 1% of deal value across repeated acquisitions, potentially exceeding $100 million over multiple years for large acquirers.
CBRE says corporate real estate teams are playing a bigger role in protecting deal value as pharmaceutical companies buy sponsor-backed biotech firms, particularly when real estate and operating systems are not fully integrated after closing.
The firm links that partial integration to a condition it calls “stranding,” where acquired companies typically have smaller real estate footprints and leaner workforces but remain only partially absorbed into the buyer’s CRE processes. CBRE notes that while financial reporting may stay intact, the operating model does not fully absorb the acquired biotech.
CBRE says signs of stranding include fragmented workplace management systems, lease renewals handled without portfolio-wide oversight, and inconsistent environmental and sustainability reporting.
To address the risk, the report recommends a playbook that includes documenting an acquired company’s real estate operations within the first 90 days and running portfolio-wide reviews every 18 to 24 months to identify integration gaps and create standardized procedures for future deals.